Notice of Intent for RNA Oligos Biological Reagents

The National Institute of Allergy and Infectious Diseases (NIAID), a component of the National Institutes of Health (NIH), has issued a Special Notice (NOI-NIAID-25-2258380) regarding a potential procurement of RNA oligos biological reagents. The notice is classified as a pre-solicitation document indicating the agency's intent to negotiate a sole source contract with Integrated DNA Technologies Inc. for specific scientific materials. The procurement falls under NAICS code 325413 for In-Vitro Diagnostic Substance Manufacturing and involves acquiring 25 units of A-tag TSO primer 1 umole RNA Oligo 1 0.3 nmol 9-11, including shipping and handling costs. The statutory authority for this sole source requirement is 41 U.S.C. 1901 (a) (1), which allows for procurement when only one responsible source can satisfy agency requirements. The delivery location for these materials is specified as Bethesda, MD 20892.

Contractors interested in this opportunity must submit capability statements through the NIAID electronic Simplified Acquisition Submission System (eSASS) by April 4, 2025, at 1:00 pm. All vendors are required to register in the eSASS system before submitting documentation, with specific registration and submission instructions available on the website. The notice is designated as a Total Small Business set-aside, potentially offering opportunities for small business contractors. While the agency intends to negotiate directly with Integrated DNA Technologies Inc., they are open to receiving capability statements from other responsible sources that could provide comparable consumables. The government retains full discretion to determine whether to compete this requirement based on the responses received. Interested contractors should carefully review the submission requirements and ensure they can meet the specific technical specifications for the RNA oligos biological reagents.